FibroBiologics (Direct Listing) FBLG 深 沪
等待开盘 09-18 09:30:00 美东时间
0.5254
-0.004
-0.77%
华盛通- 最 高0.546
- 今 开0.5376
- 成交量 24.98万股
- 最 低 0.5221
- 昨 收 0.5295
- 总市值 2200.85万
- 52周最高 3.89
- 市盈率 静 --
- 换手率 0.60%
- 52周最低 0.5221
- 委 比 82.73%
- 总股本 4188.91万
- 历史最高 55.00
- 量 比 0.47
- 振 幅 4.51%
- 历史最低 0.5221
- 每 手 1
- 风险率 4.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
FibroBiologics, Inc. has published an editorial highlighting the potential superiority of fibroblast cells over stem cells in treating chronic diseases. Authored by company leaders, the article emphasizes fibroblasts' advantages, such as faster proliferation, better sourcing, and enhanced immune modulation, for conditions like multiple sclerosis and wound healing. The company's research suggests fibroblasts could revolutionize chronic disease tre...
09-12 12:30
FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment
FibroBiologics announced positive IND-enabling updates from its psoriasis research program, highlighting the potential of human dermal fibroblast (HDF) spheroids as a novel therapeutic approach for chronic-relapse psoriasis. In acute and chronic models, a single administration of HDF spheroids demonstrated significant efficacy, matching or exceeding current treatments. The company is expanding its research to explore repeated dosing, cytokine pro...
09-11 12:30
美股大行评级 | 最高400美元！大行纷纷连夜上调甲骨文目标价；新思科技则惨遭多家大行下调目标价
今日重点评级关注：瑞银：上调Gossamer Bio评级至"买入"，目标价从1.25美元升至9美元；Canaccord Genuity：维持Corcept Therapeutics"买入"评级，目标价从137美元升至140美元
09-11 10:06
D. Boral Capital Maintains Buy on FibroBiologics, Maintains $16 Price Target
D. Boral Capital analyst Jason Kolbert maintains FibroBiologics (NASDAQ:FBLG) with a Buy and maintains $16 price target.
09-10 23:18
FibroBiologics Advances Bone Marrow Organoid Platform Offering New Treatment Options For Hematopoietic Cancers And Age-Related Immune Decline
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases
09-10 20:35
FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies
Houston-based biotech company FibroBiologics announced significant advancements in its Bone Marrow Organoid platform, offering new treatment options for hematopoietic cancers and age-related immune decline. Pre-IND animal trials demonstrated reduced tumor size in melanoma models, efficient ex vivo gene editing, and cryopreservation capabilities for scalable transplantation. The platform's versatility could enable in-vivo generation of advanced ce...
09-10 12:30
FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
FibroBiologics, Inc., a clinical-stage biotech company developing therapies for chronic diseases using fibroblast cells, announced that CEO Pete O’Heeron will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10 in New York City. The company will deliver a presentation on September 10 at 12:00 p.m. ET and hold one-on-one investor meetings during the event. For more information, visit FibroBiologics’ website or...
08-27 12:30
FibroBiologics Faces Nasdaq Delisting Notice
FibroBiologics, Inc. ( ($FBLG) ) has shared an update. On August 4, 2025, Fibro...
08-09 04:41
Watching FibroBiologics; Zacks Small-Cap Research Gives Stock $11 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_08052025_FBLG_Bautz.pdf
08-06 02:38
